Key clinical point: In patients with interstitial lung diseases at risk of pulmonary hypertension, inhaled nitric oxide produced meaningful improvements in activity.
Major finding: Treatment improved moderate to vigorous physical activity by 34% versus placebo, and demonstrated long-term maintenance of activity parameters in open-label extension data.
Study details: A 8-week randomized trial including 41 patients, and open-label extension including 18 patients.
Disclosures: Dr. Nathan provided disclosures related to Roche-Genentech, Boehringer Ingelheim, Promedior, Bellerophon, and United Therapeutics.
Nathan SD et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.308.